Alnylam Pharma's market cap is currently $56.81B. The company's EPS TTM is $1.84; its P/E ratio is 1,727.16; Alnylam Pharma is scheduled to report earnings on October 30, 2025, and the estimated EPS forecast is $1.23. See an overview of income statement, balance sheet, and cash flow financials.
